PEP-TESAMORELIN • RESEARCH USE ONLY

Tesamorelin

Tesamorelin is a potent Growth Hormone–Releasing Hormone (GHRH) analog that stimulates natural GH secretion, with a strong effect on visceral (abdominal) fat reduction and metabolic rejuvenation. This nasal formulation supports fat loss, recovery, vitality, and youthful energy through physiologic GH signaling.

10 mg

Per Bottle

— 62 mcg per spray

>99%

Purity

— Third-party verified

160

Sprays per bottle

Protocol & Dosing

Low dose Wellness, sleep, light fat-loss support

125 mcg (2 sprays) one dose evening

Medium dose Fat loss, body composition, recovery

250 mcg (4 sprays) split pre-workout + evening

Higher dose Visceral fat reduction, athletes, aggressive goals

375 mcg (6 sprays) split into 2 doses

Cycles

Use for 8–12 weeks
Take 2 weeks off after each cycle to maintain pituitary responsiveness

Key Benefits

Reduces abdominal and visceral fat, supports lean muscle maintenance, enhances metabolic function, improves recovery and sleep quality, boosts vitality, and supports anti-aging and tissue repair pathways.

Guidance

Use once daily in the evening, ideally before bed, to align with the body’s strongest natural GH pulse.
The largest natural GH surge occurs between 10:00 p.m. and 12:00 a.m., so dosing before this window helps amplify nightly GH release
For optimal effectiveness, take Tesamorelin in a fasted state
Wait at least 90 minutes after your last meal before dosing
Avoid eating for 30–60 minutes after dosing, as insulin suppresses GH release For more aggressive fat loss or athletic recovery, an optional second dose pre-workout may be used if well tolerated. Tesamorelin is more potent than CJC-1295 alone, so nasal dosing is slightl y higher.
Start with 2 sprays nightly
Increase gradually only if needed
Maintain fasted dosing for optimal GH response
Do not exceed 6 sprays per day unless directed
Ideal for visceral fat reduction, metabolic optimization, recovery, and anti-aging
Well tolerated and non-stimulatory
Pairs exceptionally well with CJC-1295 / Ipamorelin, MOTS-C, BPC-157, or TB-500 for advanced body-composition and recovery protocols

PROPRIETARY DELIVERY TECHNOLOGY

Protixa ION System™

Nasal delivery is facilitated with the Protixa ION System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange

Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.

Dual-polarity solubilization

Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.

Keratin modulation & partitioning

Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).

Superior loading vs. lipid carriers

Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Protixa ION System reaches therapeutically relevant layers.

>57× vs. saline · <10 nm (DLS)

>57× barrier penetration vs. saline in an ex vivo epithelial model (Protixa third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.

Safety, stability & distribution

ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Nasal peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117

Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA